This inventor holds 7 USPTO granted patents. Top assignees: Meiji Seika Kaisha, Ltd., Meiji Seika Kabushiki Kaisha, Meji Seika Kaisha Ltd.. Active years: 1997-2007.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Kanagawa-ken, JP (1997 - 2000)
- Yokohama, JP (1998 - 2007)
Company Filing History:


Years Active: 1997-2007
Title: Innovations of Sohjiro Shiokawa
Introduction
Sohjiro Shiokawa is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antiallergic agents. With a total of seven patents to his name, his work has had a considerable impact on medical science.
Latest Patents
Shiokawa's latest patents include innovative compounds known as tricyclic triazolobenzazepine derivatives. These compounds are designed to serve as antiallergic agents and exhibit excellent bioavailability. The patents detail a process for producing these compounds, which involves several chemical reactions to create pharmacologically acceptable salts and solvates. The compounds are represented by specific formulas, showcasing the complexity and precision of his work.
Career Highlights
Throughout his career, Sohjiro Shiokawa has worked with prominent companies in the pharmaceutical industry, including Meiji Seika Kaisha, Ltd. and Meiji Seika Kabushiki Kaisha. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the field.
Collaborations
Shiokawa has collaborated with esteemed colleagues such as Yasuo Ohtsuka and Toshio Nishizuka. These partnerships have fostered an environment of innovation and have led to the successful development of new pharmaceutical agents.
Conclusion
Sohjiro Shiokawa's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of effective antiallergic treatments, showcasing the importance of innovation in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile